Failing Cellular Recycling Lets Zombie Cells Pile Up as We Age, Study Finds

Deep inside aging tissues, cells that refuse to die quietly accumulate, spewing inflammatory molecules that damage their neighbors and drive diseases ranging from lung fibrosis to diabetes. Scientists have known for decades that these so-called zombie cells, formally called senescent cells, build up as organisms grow old, but the reasons behind their stubborn persistence have remained elusive. Now a team led by researchers at Albert Einstein College of Medicine reports that the culprit may lie in a cellular recycling system that falters with age, crippling both the zombie cells themselves and the immune cells meant to destroy them. The study, published in Nature Aging, not only explains why senescent cells evade clearance in older bodies but also demonstrates a potential pharmaceutical strategy for restoring the body’s natural defenses against them.

The research centers on chaperone-mediated autophagy, or CMA, a highly selective waste-disposal process that study leader Ana Maria Cuervo, M.D., Ph.D., has spent much of her career elucidating. Unlike other forms of autophagy that engulf bulk cellular debris, CMA relies on specialized chaperone proteins that recognize specific damaged or unnecessary proteins, unfold them, and deliver them across the lysosomal membrane for digestion and recycling. This precision matters enormously for cellular health. Cuervo, a distinguished professor of developmental and molecular biology and of medicine at Einstein and co-director of its Institute for Geroscience, previously discovered that CMA activity declines with age, and her group has since linked that decline to the accumulation of cellular garbage in neurons and other cell types, contributing to Alzheimer’s disease and other neurodegenerative conditions as well as vascular and metabolic disorders such as atherosclerosis and diabetes.

In the new work, Cuervo and her collaborators asked whether declining CMA might also explain one of aging’s most persistent mysteries: why senescent cells, which younger bodies clear away efficiently, linger and multiply in older tissues. Most of the experiments were conducted in mice, but the team also analyzed human lung tissue, finding evidence that the mechanisms they uncovered in animals may operate in people as well. The answer, it turns out, involves a double failure. Aging degrades CMA activity inside the senescent cells themselves, making them more toxic and harder to recognize, while simultaneously weakening the macrophages, the immune cells responsible for engulfing and removing them.

To appreciate the significance of this finding, it helps to understand that zombie cells are not always villains. During wound healing, for example, some injured cells deliberately enter a senescent state and release signaling substances that recruit other cells to the site of injury, orchestrating tissue repair. In a healthy young body, this is a carefully timed operation: the senescent cells do their job, and then macrophages, essential immune cells that fight infection, clear dead cells, and regulate inflammation, arrive to sweep them away. When the researchers genetically engineered mice whose macrophages lacked CMA, they found that these animals accumulated more zombie cells at wound sites and healed more slowly than control mice, demonstrating that CMA within macrophages is essential for clearing senescent cells that would otherwise interfere with tissue repair.

The team then zoomed in on the process of zombification itself. Scientists can create senescent cells in the laboratory by exposing them to drugs that halt cell division, and when the researchers did this with fibroblasts, cells found in connective tissue, taken from young and old mice, they observed striking differences. Fibroblasts from young mice ramped up their CMA activity as they became senescent, apparently as part of a controlled transition. Fibroblasts from old mice, which already had low CMA activity, failed to increase it at all. That failure had cascading consequences. Certain proteins inside the old senescent cells were never properly broken down through CMA, and the cells consequently secreted undigested toxic substances into their surroundings. Those secretions did two kinds of damage: they pushed nearby healthy cells toward senescence themselves, spreading the zombie population, and they interfered with macrophages’ ability to recognize and remove the senescent cells, allowing them to hide in plain sight.

Meanwhile, the macrophages of older animals were fighting their own battle. The researchers found that CMA activity in macrophages from aged mice was significantly lower than in those from young animals, and this deficit reduced the immune cells’ capacity to engulf and eliminate senescent cells. In other words, aging simultaneously makes zombie cells more numerous, more poisonous, and better camouflaged, while disarming the very immune soldiers tasked with destroying them. It is a vicious circle in which each failing reinforces the others, and it helps explain why senescent cell burden rises so steeply in later life and why that burden correlates so strongly with chronic inflammation and age-related disease.

These findings carry an important caution for the booming field of senolytics, drugs designed to kill senescent cells outright. Since scientists first recognized that zombie cells help drive the aging process, pharmaceutical researchers have pursued compounds to eliminate them, but the new results suggest that testing such drugs on cells taken from young animals and artificially made senescent in the laboratory may not predict how they will perform in older bodies, where the biology of senescence is fundamentally altered. The Einstein team points toward a different approach: rather than killing zombie cells directly, use a compound that reactivates CMA, reducing the harmful effects of their secretions while simultaneously restoring macrophages’ ability to recognize and engulf them. In essence, the goal shifts from assassination to rehabilitation, coaxing the aging body’s own clearance machinery back into working order.

Encouragingly, the researchers had already developed such a tool. A small-molecule CMA activator called CA77.1, created in earlier work by the Cuervo laboratory, was put to the test in aged mice. After five months of daily oral treatment, the animals showed reduced buildup of zombie cells in several organs, along with diminished signs of inflammation and fibrosis. In a separate experiment, macrophages isolated from aged mice and treated with CA77.1 recovered their ability to engulf particles to levels comparable to macrophages from young mice, evidence that the drug can functionally rejuvenate aging immune cells rather than merely slowing further decline.

The final step was to ask whether any of this could matter for human disease, and the team chose a particularly grim candidate: idiopathic pulmonary fibrosis, or IPF, a condition in which scar tissue progressively invades the lungs, making breathing increasingly difficult. Median survival after diagnosis is only three to five years, and the disease is tightly connected to cellular senescence. When the researchers examined lung samples from IPF patients, they found markedly reduced CMA activity, raising the possibility that a CMA-boosting drug might help. Testing in a mouse model of the disease delivered promising results: when treatment with CA77.1 was begun early after lung injury, it reduced the severity of lung fibrosis as well as markers of cellular senescence and inflammation.

Our research connects two major drivers of aging, declining CMA and cellular senescence, and shows for the first time how their interaction allows senescent cells to evade clearance by the immune system in old organisms, Cuervo said. We have also found that instead of trying to kill zombie cells, we may be able to restore their interaction with the immune system so that the body can clear them naturally. The next challenge, she noted, is determining whether this approach can eventually be developed into a safe treatment for age-related diseases in people. The paper, first authored by Rebecca Sereda, who conducted the work as a graduate student in Cuervo’s laboratory co-mentored by Susmita Kaushik, drew on researchers from two additional Einstein laboratories and three external collaborating groups at Ohio State University, the Centre de Recherche des Cordeliers and Gustave Roussy, and the University of Pittsburgh. It was supported by the NIH National Institute on Aging, the Hevolution Foundation, the Freedom Together Foundation, and the Rainwaters Foundation, and it grew out of an Einstein Hevolution Partnership Award. Albert Einstein College of Medicine holds a portfolio of intellectual property related to the research and is seeking licensing partners to develop and commercialize the technology. If future studies confirm that boosting CMA is safe and effective in humans, the work could mark a turning point in geroscience, replacing the blunt instrument of cell killing with a subtler strategy: teaching an aging immune system to remember how to clean up after itself.

Subject of Research: Age-related decline in chaperone-mediated autophagy and its role in senescent cell accumulation

Article Title: Einstein researchers discover why “zombie cells” accumulate with age

Article References: Einstein researchers discover why “zombie cells” accumulate with age. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: senescent cells, zombie cells, chaperone-mediated autophagy, aging, macrophages, lung fibrosis, CA77.1, inflammation, geroscience, senolytics, Nature Aging, immunosenescence